Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Adenocarcinoma Stage IIIB/IV: early-phase trial registry
1 of 2 indexed Lung Adenocarcinoma Stage IIIB/IV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Lung Adenocarcinoma Stage IIIB/IV: 2 US clinical trials tracked, 1 recruiting.
Lung Adenocarcinoma Stage IIIB/IV is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Barbara Nemesure, running 1 of these trials.
Enrollment posture brief
Registry condition lung-adenocarcinoma-stage-iiibiv
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Lung Adenocarcinoma Stage IIIB/IV lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Adenocarcinoma Stage IIIB/IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Adenocarcinoma Stage IIIB/IV is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
Barbara Nemesure
NCT07161713
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
EMD Serono Research & Development Institute
NCT02864992
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Adenocarcinoma Stage IIIB/IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Adenocarcinoma Stage IIIB/IV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Adenocarcinoma Stage IIIB/IV page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lung Adenocarcinoma Stage IIIB/IV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Barbara Nemesure sponsors the most Lung Adenocarcinoma Stage IIIB/IV trials on record, review their full trial history before evaluating a specific study. See Barbara Nemesure's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Adenocarcinoma Stage IIIB/IV condition card totals 2 registered trials; most-linked intervention Tepotinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.